Rodent-associated Bartonella Febrile Illness, Southwestern United States by Iralu, Jonathan et al.
Serum specimens from 114 patients hospitalized with
a febrile illness were tested with an indirect immunofluores-
cence assay (IFA) using Bartonella antigens prepared from
6 species of sigmodontine rodents and 3 known human
Bartonella pathogens:  B. henselae,  B. quintana, and B.
elizabethae. Acute- and convalescent-phase serum sam-
ples from 5 of these patients showed seroconversion with
an IFA titer >512 to rodent-associated Bartonella antigens.
The highest titer was against antigen derived from the
white-throated woodrat (Neotoma albigula), although this
rodent is not necessarily implicated as the source of infec-
tion. Three of the 5 who seroconverted showed no cross-
reaction to the 3 Bartonella human pathogens. Common
clinical characteristics were fever, chills, myalgias, leukope-
nia, thrombocytopenia, and transaminasemia. Although
antibodies to Bartonella are cross-reactive, high-titer sero-
conversions to rodent-associated Bartonella antigens in
adults with common clinical characteristics should stimu-
late the search for additional Bartonella human pathogens.
T
he discovery of hantavirus pulmonary syndrome and
its high death rate in the southwestern United States
resulted in greater vigilance in evaluating patients with
acute febrile illness, particularly those with thrombocy-
topenia (1). Clinicians soon became aware of substantial
numbers of hospitalized patients with a severe flulike pro-
drome and thrombocytopenia. In spite of conventional cul-
ture and serologic analysis for known pathogens and
diseases, including hantaviruses, plague, tularemia, relaps-
ing fever, spotted fever, murine typhus, and Q fever, no
diagnosis could be made. To assist physicians in identify-
ing treatable pathogens, we submitted serum to reference
laboratories for diagnostic seroassays directed at known
pathogens and organisms not previously associated with
human disease. A concept of the role of rodent-associated
bartonellae as a cause of unexplained febrile illness in the
western United States has been recently developed (M.
Kosoy, pers. comm.). We considered the possibility that
some cases in our study were caused by Bartonella
species.
Among at least 20 known species and subspecies of
Bartonella, 5 have been identified as causes of human dis-
ease in North America (2,3). B. henselae causes cat-scratch
disease with regional lymphadenitis and occasionally
hepatosplenic disease in the immunocompetent host, and
bacillary angiomatosis, cerebritis, or peliosis hepatis in the
immunocompromised host (4–6). Louseborne B. quintana
causes trench fever, aseptic meningitis, bacteremia, endo-
carditis, or bacillary angiomatosis (4,7–9). Recently isolat-
ed cases of infection with B. elizabethae (10), B. vinsonii
subsp. arupensis (11), and B. washoensis (12) suggest that
the spectrum of Bartonella infections may continue to
expand.
Many mammals, including numerous species of
rodents, are commensally infected with Bartonella species
in North America (12–15). We sought serologic evidence
for human bartonellae infection in serious febrile illnesses
in the Four Corners region, using diverse Bartonella anti-
gens in an indirect immunofluorescence assay (IFA) (13).
We report 7 years’ cumulative experience in diagnostic
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From July 1993 to June 2001, 114 patients 15–78 years
of age were referred by their physicians for assistance in
diagnosing a febrile illness with a duration <12 days at the
time of admission. One hundred patients were hospitalized
in New Mexico, 10 in Arizona, and 4 in Colorado. All
patients were hospitalized on the basis of the attending
physician’s decision concerning severity of illness, the
possibility of hantavirus infection in the prodrome phase,
and the need for diagnostic studies, supportive care, and
presumptive antimicrobial-drug therapy. At the time spec-
imens were collected, results of conventional microbiolog-
ic assays and diagnostic serologic analysis were negative
or unavailable.
Patients were divided into 4 clinical groups according
to conventional diagnostic results (Table 1). Seventy-six
patients (group A) had an acute undifferentiated febrile ill-
ness without pulmonary, cardiac, or renal manifestations.
Twelve patients (group B) had bacterial lobar pneumonia
(11 patients) or acute respiratory distress syndrome (1
patient) diagnosed by typical signs and symptoms, hypox-
emia, pulmonary infiltrates, and prompt clinical response
to β-lactam antimicrobial drugs (16,17). Twelve patients
(group C) had hantavirus cardiopulmonary syndrome diag-
nosed by strip immunoblot serology (18) and reverse tran-
scription–polymerase chain reaction (RT-PCR) of serum
(19). Fourteen patients (group D) had an acute febrile syn-
drome without pulmonary manifestations and with a diag-
nosis established by conventional blood culture, serology,
or PCR; this group included 3 patients with Escherichia
coli sepsis, 2 with E. coli pyelonephritis, 3 with Rocky
Mountain spotted fever, 1 with acute Staphylococcus
aureus aortic valve endocarditis, 1 with bubonic plague, 1
with acute Q fever, 1 with parvovirus infection, 1 with
acute rheumatic fever, and 1 with acute lupus erythemato-
sis. All patients (except those in group D) had at least 2
negative blood cultures, negative spinal fluid cultures and
cytometrics when appropriate, negative hantavirus sero-
logic results (except group C), and negative serologic
results for plague, tularemia, Q fever, spotted fever, and
Ehrlichia species ordered at the discretion of the attending
physician. Except for hypertension (5 patients) and chron-
ic alcoholism (12 patients), no patient had underlying dis-
ease such as diabetes, malignancy, or HIV infection. The
charts were reviewed retrospectively by the investigators.
The study was approved by the institutional review boards
of the University of New Mexico and the Navajo Nation.
Serologic Analysis
Citrated and clotted blood was collected within 24
hours of admission from 90 patients (acute-phase sample),
7–42 days after admission from 10 patients, and at admis-
sion and during convalescence from 14 patients (all in
group A). Plasma was immediately frozen at –80°C. An
IFA was performed as previously described (13). All anti-
gens were prepared at the Bacterial Zoonoses Branch,
Centers for Disease Control and Prevention (CDC), Fort
Collins, Colorado. 
Vero E6 monolayers were infected separately with 1 of
9 strains of Bartonella: 3 strains (B. quintana, B. henselae,
and  B.  elizabethae) were isolated from humans and 6
strains were isolated from the meadow vole (Microtus
pennsylvanicus), white-throated woodrat (N.  albigula),
deer mouse (Peromyscus maniculatus), cotton rat
(Sigmodon hispidus), Ord kangaroo rat (Dipodomys ordi),
and rock squirrel (Spermophilus variegatus). Plasma was
diluted 1:32 in phosphate-buffered saline, placed in anti-
gen-containing wells, incubated at 37°C for 30 minutes,
washed, and incubated at 37°C for 30 minutes with rabbit
antihuman immunoglobulin (Ig) conjugated with fluores-
cein isothiocyanate. Positive samples were then tested in
serial 2-fold dilutions on monolayers infected with 1 of 9
Bartonella strains. Mouse hyperimmune sera were pro-
duced by injection of BALB/c mice with the same
Bartonella strains that were used for the antigen prepara-
tions. These sera were used as IFA-positive controls (titers
>1,000 in each assay). Results were tabulated without
knowledge of the patient’s clinical status.
Results
Serum samples from 114 patients with acute febrile ill-
ness, including 14 with both acute- and convalescent-
phase serum samples, were tested at a dilution of 1:32 by
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samples were retested at a dilution of 1:32 and at doubling
dilutions to 1:4,096. In 12 of 13 cases with titers <512 to
any rodent-associated antigen, the titer to the N.
albigula–associated  Bartonella antigens (NA-AB anti-
gens) were the highest measured. Therefore, only the titers
to NA-AB antigens are shown in Table 1. IFAtiters to NA-
AB >128 were observed more often in undifferentiated
febrile illness (group A, 24 of 76) than in the 3 groups with
specific diagnoses (groups B–D, 4 of 38) (χ2 = 4.98, p =
0.026, using Yates’ correction). Among 24 patients in
group A with titers >128, a total of 11 had convalescent-
phase titers >512. Clinical information was sufficient to
analyze for 9 of these 11 patients: 5 patients with both
acute- and convalescent-phase titers (Table 2) and 4
patients with only a convalescent-phase titer (Table 3).
Nine patients in group A with both acute- and convales-
cent-phase serum samples showed no increase in titer or a
titer >64.
Of 24 patients with pneumonic disease (groups B and
C), only 1 had a titer of 128 to NA-AB antigens. Of 14
patients with other diagnosed febrile illnesses (group D)
not listed in Tables 2 and 3, three had high titers to NA-AB
antigens (Table 1). A 35-year-old man with aortic valve
endocarditis and cultures of blood and valve positive for S.
aureus had an NA-AB titer of 1,024 on admission and the
following day. A 30-year-old man with fever, myalgias,
headache, thrombocytopenia, and leukopenia with admis-
sion serum positive by PCR for Borrelia hermsii (tick-
borne relapsing fever) had an acute-phase (day 1) titer of
256 and a convalescent-phase (day 24) titer of 1,024 to
NA-AB antigens. A 23-year-old woman with fever and
acute hepatic injury had positive convalescent-phase (day
28) IgM phase I (512) and IgG phase II (1,024) titers for
Coxiella burnetii antigens and an NA-AB antigen titer of
256 in a convalescent-phase serum sample.
Five of the 14 patients with acute- and convalescent-
phase serum samples in group Ashowed a >4-fold increase
in titer to NA-AB antigens and convalescent-phase titers
>512 on days 14, 7, 7, 12, and 42, respectively, after
admission (Table 2). Each of the 5 who seroconverted had
a clinical syndrome characterized by fever (temperature
>39°C), chills, pronounced myalgias in the back and
thighs, nausea, and headache. Two who seroconverted had
a sore throat and 2 had diarrhea, but none had other upper
or lower respiratory symptoms, abnormal chest radiograph
results, lymphadenopathy, hepatosplenomegaly, bleeding,
rash, altered consciousness, or abnormal neurologic find-
ings. Thrombocytopenia and leukopenia were common
(Tables 2 and 3), but no patients had evidence of coagu-
lopathy, or cardiac, pulmonary, renal, or neurologic dis-
ease. 
Four other patients in group Ahad a single titer >512 to
NA-AB antigens on days 21, 7, 20, and 23, respectively,
after admission (Table 3). This group had elevated levels
of serum transaminase, bilirubin, and alkaline phos-
phatase, which is indicative of active hepatitis. These 4
patients were treated with doxycycline, and all recovered
without sequelae. Of the 9 patients listed in Tables 2 and 3,
one had a diagnosis of chronic alcoholism (patient 6, Table
3). All 9 were negative for hepatitis A, B, and C; Q fever;
Rocky Mountain spotted fever; murine typhus; leptospiro-
sis; granulocytic or monocytic ehrlichiosis; plague; and
tularemia; they also had negative titers for HIV, hantavirus,
and antinuclear antibody. Patients 6, 8, and 9 were tested
for antibody to hepatitis E at the Hepatitis Branch of CDC
in Atlanta, Georgia, and were negative (M. Favorov, pers.
comm.). Patients 1, 4, and 6 had 6-, 3-, and 3-fold lower
titers, respectively, to the known Bartonella pathogen anti-
gens compared with the titer to NA-AB antigens (Tables 2
and 3).
Rodent-associated Bartonella Illness
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This study provides preliminary serologic evidence for
a Bartonella or Bartonella cross-reactive species that is
causing acute febrile illness in immunocompetent adults in
the rural southwestern United States. Five patients who
seroconverted to rodent-associated antigen had fever,
myalgias, headache, and chills with varying degrees of
leukopenia, mild hepatitis, and thrombocytopenia. Four
other patients with a single elevated titer 2–5 weeks into
their illness had more severe hepatic injury. In the absence
of culture- or PCR-positive evidence of Bartonella infec-
tion in any of these patients, the interpretation of these
serologic observations is related to the cross-reactivity
between  Bartonella species as well as non-Bartonella
species, interpretation of the quantitative IFA titer, varia-
tions among pathogens to stimulate antibody responses,
timing of serum specimen collection, and the route of
exposure.
Although antigens derived from Bartonella isolated
from N. albigula were used, this process does not imply
that the human infection was caused by a Bartonella strain
that naturally infects N. albigula. Serologic cross-reactions
among Bartonella species are common (20), and the IFAis
unable to distinguish between infection with B. quintana
or B. henselae (21). The cross-reactivity between rodent-
associated and known Bartonella pathogen–associated
antigens was expected and found to some degree in nearly
all cases. We did not find clear evidence for infection with
Bartonella species known to cause disease in humans,
including B. henselae, B. quintana, B. vinsonii, and B. eliz-
abethae, in the sense that titers to rodent-associated, partic-
ularly NA-AB, antigens were always higher than those for
known human Bartonella species. The lack of cross-reac-
tivity in 3 patients is consistent with a rodent-associated
Bartonella infection, although infection with a Bartonella
associated with a nonrodent animal cannot be ruled out
(22). 
Identification of Bartonella infections in humans in the
southwestern United States is important because cat-
scratch disease is not common in this region, and cat fleas,
presumed vectors for B. henselae, do not naturally exist in
such arid environments (23). Cross-reactivity between
Bartonella antigens and antigens of C.  burnetii and
Chlamydia species has been demonstrated (24,25). Except
for the woman in group D who had clear evidence of acute
Q fever hepatitis, significant Bartonella titers >128 were
not associated with detectable antibody to phase I or II
Coxiella antigens in the complement fixation test in all 8
patients tested. None of the patients had a condition asso-
ciated with nonspecific immune stimulation such as HIV
infection, injection drug use, or collagen vascular disease
that could account for false-positive results.
The IFA was developed at CDC (21) and has been
assessed most extensively in the diagnosis of B. henselae
and B. quintana infection in the United States (20). At the
National Referral Center of CDC, a titer of 64 is considered
positive (20). When a strict case definition is used for cat-
scratch disease, this titer has a sensitivity of ≈80% and a
specificity of 93% to 96% (20,21,26). Other investigators
have found greater specificity when titers of 128 (27), 256
(25), or 512 (28) were used to diagnose cat-scratch disease.
An IFA titer of 512 to B. henselae in adults with no expo-
sure to cats or illness compatible with cat-scratch disease
was uncommon (<1%) in 1 study in Germany (27). We
used a conservative threshold IFA titer of 512 to present
clinical data on 9 patients based in part on this experience
with cat-scratch disease, recognizing that immunogenicity
to immunodominant antigens may vary among species of
the same genus. The usefulness of a single titer of 1:512 to
NA-AB antigens (Table 3) is unknown because IFAtiters to
B. henselae persist during the first year after infection (20).
The clinical syndrome associated with seroconversion
to NA-AB antigens was characterized by either a brief
undifferentiated febrile illness or fever accompanied by
hepatic injury. Clinical evidence for inflammation in the
lung, heart, kidney, and nervous system was not apparent.
Infection with B.  henselae, particularly in immunocom
promised hosts, has been documented to involve the liver
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were common in our small sample of febrile patients, have
also been associated with B.  quintana infection (29) in
immunocompetent adults and with B. henselae infection in
immunocompromised adults (2). No patient had intraery-
throcytic bacilli visible on Giemsa-stained blood smear
(30) (F. Koster, unpub. data). A clear definition of the syn-
drome awaits definitive identification based on culture of
the pathogenic species from patients. Thus, a concerted
effort to identify acute infections with rodent-associated
Bartonella should be undertaken with specific serologic
assays as well as intensive PCR-based diagnostics and cul-
ture techniques specific to the fastidious Bartonella genus.
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